Fosun Pharma's HLX10 (Serplulimab) Included in Breakthrough Therapy Program for Gastric Cancer Treatment

Stock News11-20

Fosun Pharma (600196.SH) announced that its self-developed anti-PD-1 monoclonal antibody, HLX10 (Serplulimab), has been included in China's Breakthrough Therapy Designation program for the neoadjuvant/adjuvant treatment of gastric cancer (GCneo) in combination with chemotherapy. The drug, marketed as HANSIZHUANG® in China, was developed by Fosun Pharma's subsidiary Shanghai Henlius Biotech and its affiliates.

As of the announcement date, no PD-1-targeted monoclonal antibody therapy has been approved globally for gastric cancer neoadjuvant/adjuvant treatment. According to the latest IQVIA MIDAS™ data, global sales of PD-1-targeted monoclonal antibodies reached approximately $45.704 billion in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181434156?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181434156","market":"sg","top_or_hot":-1,"title":"Fosun Pharma's HLX10 (Serplulimab) Included in Breakthrough Therapy Program for Gastric Cancer Treatment","media":"Stock News","content":"<p>Fosun Pharma (600196.SH) announced that its self-developed anti-PD-1 monoclonal antibody, HLX10 (Serplulimab), has been included in China's Breakthrough Therapy Designation program for the neoadjuvant/adjuvant treatment of gastric cancer (GCneo) in combination with chemotherapy. The drug, marketed as HANSIZHUANG® in China, was developed by Fosun Pharma's subsidiary Shanghai Henlius Biotech and its affiliates.</p>\n<p>As of the announcement date, no PD-1-targeted monoclonal antibody therapy has been approved globally for gastric cancer neoadjuvant/adjuvant treatment. According to the latest IQVIA MIDAS™ data, global sales of PD-1-targeted monoclonal antibodies reached approximately $45.704 billion in 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma's HLX10 (Serplulimab) Included in Breakthrough Therapy Program for Gastric Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma's HLX10 (Serplulimab) Included in Breakthrough Therapy Program for Gastric Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-20 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fosun Pharma (600196.SH) announced that its self-developed anti-PD-1 monoclonal antibody, HLX10 (Serplulimab), has been included in China's Breakthrough Therapy Designation program for the neoadjuvant/adjuvant treatment of gastric cancer (GCneo) in combination with chemotherapy. The drug, marketed as HANSIZHUANG® in China, was developed by Fosun Pharma's subsidiary Shanghai Henlius Biotech and its affiliates.</p>\n<p>As of the announcement date, no PD-1-targeted monoclonal antibody therapy has been approved globally for gastric cancer neoadjuvant/adjuvant treatment. According to the latest IQVIA MIDAS™ data, global sales of PD-1-targeted monoclonal antibodies reached approximately $45.704 billion in 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1181434156","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181434156","pubTimestamp":1763629483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Fosun Pharma (600196.SH) announced that its self-developed anti-PD-1 monoclonal antibody, HLX10 (Serplulimab), has been included in China's Breakthrough Therapy Designation program for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0188":"融资融券","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","PD":"PagerDuty, Inc.","02196":"复星医药","BK1515":"抗疫概念","BK0187":"一线龙头","BK1191":"制药","BK0175":"白马股","BK1593":"医美概念股","BK0060":"抗癌","BK4023":"应用软件","BK0183":"MSCI概念","BK0096":"民营医院","BK0239":"医药制造","BK0012":"证金概念","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK0028":"国家队","BK0196":"行业龙头"},"translate_title":"复星医药HLX10（Serplulimab）纳入胃癌治疗突破性疗法计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"PD":1,"02196":1},"content_text":"Fosun Pharma (600196.SH) announced that its self-developed anti-PD-1 monoclonal antibody, HLX10 (Serplulimab), has been included in China's Breakthrough Therapy Designation program for the neoadjuvant/adjuvant treatment of gastric cancer (GCneo) in combination with chemotherapy. The drug, marketed as HANSIZHUANG® in China, was developed by Fosun Pharma's subsidiary Shanghai Henlius Biotech and its affiliates.\nAs of the announcement date, no PD-1-targeted monoclonal antibody therapy has been approved globally for gastric cancer neoadjuvant/adjuvant treatment. According to the latest IQVIA MIDAS™ data, global sales of PD-1-targeted monoclonal antibodies reached approximately $45.704 billion in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181434156","isCrawlerRequest":true}